Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6012 in Acute STEMI
NCT03578809Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 10
01
Overview
A Phase 2 trial of recombinant human lecithin-cholesterol acyltransferase in ST elevation myocardial infarction (STEMI), sponsored by MedImmune. Started Jun 2018; status: completed.
02
Drugs
recombinant human lecithin-cholesterol acyltransferase
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03578809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578809.